0085-1318 : Rebetol 40 mg/ml Oral Liquid

Labeler: Merck Sharp & Dohme Corp.
Product Type: Human Prescription Drug
Drug Name:  Rebetol
Dosage Form: Oral Liquid
Application #: NDA021546
Rev. Date: 

NDC Package Codes:

  • 0085-1318-01: 1 BOTTLE IN 1 CARTON (0085‑1318‑01) > 100 ML IN 1 BOTTLE

Active Ingredients:

  • Ribavirin

Dosage Strength:

  • 40 mg/mL

Pharmaceutical Classes:

  • Nucleoside Analog Antiviral [EPC]
  • Nucleoside Analog [EXT]

Related Products:

Based on records with the same trade name.
  • 0085-1194 Rebetol 200 mg Oral Capsule by Merck Sharp & Dohme Corp.
  • 0085-1351 Rebetol 200 mg Oral Capsule by Merck Sharp & Dohme Corp.
  • 0085-1385 Rebetol 200 mg Oral Capsule by Merck Sharp & Dohme Corp.


Scan the QR code below to easily reference this data in the future:

NDC 0085-1318 QR Code

< Prev: 0085-1317Next: 0085-1322 >

Related Discussions:

Ribavirin-Interferon long term side effects
Hi. I was treated for chronic Hep C 20 years ago and been having continuous health problems arise over past 5 years. I w... 3 replies
Ribavirin reaction
I took peginterferon shots once a week with 6 ribavirin tablets a day. I had skin reactions and scatched all the hair of... 3 replies
sovaldi and ribavirin
66 years old, geno 2, 24 mo treatment, just finished treatment jan.5, 2015, now feb 8, still have headaches, itching, an... 4 replies
drug interaction with sovaldi and ribavirin
can you take lithium while taking sovaldi and ribavirin ## Hello, Polly! How are you? I didn't find any interactions... 2 replies
Dear sir; requesting your kind assistance to provide me with the AMERICAN EQUIVALENT DRUG NUMBER (AE) of:- 1- Pegasys in...

Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.